Theta burst stimulation (TBS) in methamphetamine use disorder: a meta-analysis and systematic review.

J Addict DisAug 4, 2025 (epub)
Clinical ResearchPsychiatry

Gopalkumar Rakesh, Thomas G Adams, Dylan H Ballard et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed theta burst stimulation (TBS) for cue-induced methamphetamine craving in people with methamphetamine use disorder (MUD). It included randomized controlled trials using unique participant cohorts, identified through searches up to September 1, 2024. In a meta-analysis of four sham-controlled trials, intermittent TBS (iTBS) reduced craving more than sham iTBS, with a standardized mean difference in change of 1.04 (95% CI [0.16, 1.92]). Two additional trials without sham controls were reviewed; one reported a significant craving reduction after accelerated iTBS.

Key findings

  • Across four sham-controlled RCTs, iTBS reduced cue-induced craving more than sham iTBS (SMD in change = 1.04; 95% CI [0.16, 1.92]).
  • Of two additional RCTs without sham control arms, one found a significant reduction in craving following accelerated iTBS.

Why it matters

MUD lacks FDA-approved treatments, and craving is a relevant treatment outcome. The pooled result provides evidence that iTBS may reduce cue-induced craving compared with sham, while highlighting the need to assess outcomes beyond craving, including methamphetamine use and return to use.

What to keep in mind

The meta-analysis included only four eligible sham-controlled RCTs and assessed craving rather than methamphetamine use or return to use. Two additional trials lacked sham control arms.

Source

Published in J Addict Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.